Prasad Narayan, Bansal Shyam Bihari, Yadav Brijesh, Manhas Neha, Yadav Deependra, Gautam Sonam, Kushwaha Ravishankar, Singh Ankita, Bhadauria Dharmendra, Yachha Monika, Behera Manas Ranjan, Kaul Anupama
Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Medanta The Medicity Hospital, Gurgaon, India.
Front Immunol. 2022 Jun 30;13:911738. doi: 10.3389/fimmu.2022.911738. eCollection 2022.
Vaccination is an effective strategy for preventing SARS-CoV-2 infection and associated mortality. Renal Transplant Recipients (RTRs) are vulnerable to acquiring infection and high mortality due to their immunocompromised state. Varying responses to the different vaccines, depending on types of vaccines and population, have been reported. Vaccines supply is also limited. The current study evaluated the seroconversion rate after SARS-CoV-2 infection and 2 doses of either COVAXIN™ or COVISHIELD™ vaccination in RTR.
The serum anti-SARS-CoV-2 spike protein neutralizing antibody titer was measured in 370 RTRs who acquired SARS-CoV-2 infection (n=172), yet not vaccinated; and those vaccinated with COVAXIN™ (n=78), and COVISHIELD™ (n=120) by chemiluminescence microparticle immunoassay methods from serum.
Overall, the seroconversion rate either after vaccination or infection was 85.13% (315/370). The vaccine-associated seroconversion was 80.30% (159/198). SARS-CoV-2 infection-associated seroconversion was 90.69% (156/172), COVISHIELD™ associated seroconversion was 79.2% (95/120), and COVAXIN™ associated seroconversion was 82.05% (64/78). The median IgG titer in the SARS-CoV-2 infection group was 646.50 AU/ml (IQR: 232.52-1717.42), in the COVAXIN™ group was 1449.75 AU/ml (IQR: 400.0-3068.55), and the COVISHIELD™ vaccination group was 1500.51 AU/ml (IQR: 379.47-4938.50). The seroconversion rate and antibody titers were similar irrespective of the place of sampling. Patient's age-associated seroconversion in <45 years was 88.01% (213/242), 45.1-60 years was 83.18% (94/113), and > 60 years was 58.3% (7/12).
Both infection and vaccination induce robust antibody formation in RTRs. The seroconversion rate after SARS-CoV-2 infection was higher but with a lower antibody titer than vaccines. The vaccines, COVAXIN™ and COVISHIELD™, induce more elevated antibody titers than natural infection. The seroconversion rate and antibody titer in Indian RTRs appears to be better than in the western population, irrespective of their vaccination status.
接种疫苗是预防严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染及相关死亡的有效策略。肾移植受者(RTRs)由于免疫功能低下,易感染且死亡率高。根据疫苗类型和人群的不同,对不同疫苗的反应也有所不同。疫苗供应也有限。本研究评估了SARS-CoV-2感染以及肾移植受者接种两剂COVAXIN™或COVISHIELD™疫苗后的血清转化率。
采用化学发光微粒子免疫分析方法,检测了370例感染SARS-CoV-2但未接种疫苗的肾移植受者(n = 172)、接种COVAXIN™(n = 78)和接种COVISHIELD™(n = 120)的肾移植受者血清中抗SARS-CoV-2刺突蛋白中和抗体滴度。
总体而言,接种疫苗或感染后的血清转化率为85.13%(315/370)。疫苗相关血清转化率为80.30%(159/198)。SARS-CoV-2感染相关血清转化率为90.69%(156/172),COVISHIELD™相关血清转化率为79.2%(95/120),COVAXIN™相关血清转化率为82.05%(64/78)。SARS-CoV-2感染组的IgG滴度中位数为646.50 AU/ml(四分位间距:232.52 - 1717.42),COVAXIN™组为1449.75 AU/ml(四分位间距:400.0 - 3068.55),COVISHIELD™接种组为1500.51 AU/ml(四分位间距:379.47 - 4938.50)。无论采样地点如何,血清转化率和抗体滴度相似。年龄小于45岁患者的血清转化率为88.01%(213/242),45.1 - 60岁为83.18%(94/113),大于60岁为58.3%(7/12)。
感染和接种疫苗均可在肾移植受者中诱导产生强大的抗体。SARS-CoV-2感染后的血清转化率较高,但抗体滴度低于疫苗。COVAXIN™和COVISHIELD™疫苗诱导产生的抗体滴度高于自然感染。无论疫苗接种状态如何,印度肾移植受者的血清转化率和抗体滴度似乎均优于西方人群。